Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Lu AG13909

Generic Name: Lu AG13909

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

Phase 2

Recruiting

Posted: 2024/06/24

Sponsor:H. Lundbeck A/S

ID:NCT06471829

Study of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

Phase 1

Recruiting

Posted: 2023/01/03

Sponsor:H. Lundbeck A/S

ID:NCT05669950

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Crinecerfont Shows Promise in Pediatric Congenital Adrenal Hyperplasia Across All Patient Subgroups

16 days ago

Phase 3 CAHtalyst pediatric study demonstrates that crinecerfont (CRENESSITY) effectively reduces glucocorticoid dosing while maintaining or improving androstenedione levels in children with classic congenital adrenal hyperplasia.

Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion, Bolstering Epilepsy Pipeline

7 months ago

Lundbeck will acquire Longboard Pharmaceuticals for $2.6 billion, gaining bexicaserin, a promising drug for developmental and epileptic encephalopathies (DEEs).

FDA Grants Priority Review to Crinecerfont for Congenital Adrenal Hyperplasia

8 months ago

The FDA has accepted two New Drug Applications for Neurocrine Biosciences' crinecerfont, granting Priority Review for treating classic congenital adrenal hyperplasia (CAH).

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy